Day 0 Inclusion Assessment Window Lab confirmed COVID Days 14 3 Washout for exposure No use of famotidine Days 90 1 Exclusion Assessment Window Use of Intensive services Days 90 0 ID: 1046387
Download Presentation The PPT/PDF document "Date of admission to hospital" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Date of admission to hospitalDay 0Inclusion Assessment WindowLab confirmed COVID Days [-14, 3]Washout for exposureNo use of famotidineDays [-90, -1]Exclusion Assessment WindowUse of Intensive servicesDays [-90, 0]Covariate Assessment WindowRisk factors for deathDays [-90, 0]Day 0A. Original design visualization frameworkExposure Assessment WindowAdministration of famotidine Day [0, 0]1 Censor on death, discharge, end of study periodFollow-upDays [1, censor1]
2. Inclusion Assessment WindowLab confirmed COVID Days [-14, 3]Washout for exposureNo use of famotidineDays [-90, -1]Exclusion Assessment WindowUse of Intensive servicesDays [-90, 0]Covariate Assessment WindowRisk factors for deathDays [-90, 0]Follow-upDays [1, censor1]Day 0B. Design applied in a commercial claims database with data observability linesInclusion Assessment WindowContinuous enrollmentDays [-90, 0]Observable DataIncomplete ObservabilityNo ObservabilityDate of admission to hospitalDay 0Exposure Assessment WindowAdministration of famotidineDay [0, 0]Outpatient Dx, Px, RxOutpatient Lab resultsInpatient Rx, LabInpatient Dx, Px1 Censor on death, discharge, end of study periodIn-hospital death
3. Inclusion Assessment WindowLab confirmed COVID Days [-14, 3]Washout for exposureNo use of famotidineDays [-90, -1]Exclusion Assessment WindowUse of Intensive servicesDays [-90, 0]Covariate Assessment WindowRisk factors for deathDays [-90, 0]Day 0Observable DataIncomplete ObservabilityNo ObservabilityDate of admission to hospitalDay 0Exposure Assessment Window Administration of famotidine Day [0, 0]Outpatient Dx, Px, RxOutpatient Lab resultsInpatient Dx, Px, Rx, LabC. Design applied in a hospital EHR-based research databaseFollow-upDays [1, censor1]1 Censor on death, discharge, end of study periodIn-hospital death
4. Inclusion Assessment WindowLab confirmed COVID Days [-14, 3]Washout for exposureNo use of famotidineDays [-90, -1]Exclusion Assessment WindowUse of Intensive servicesDays [-90, 0]Covariate Assessment WindowRisk factors for deathDays [-90, 0]Day 0Inclusion Assessment WindowContinuous enrollmentDays [-90, 0]Date of admission to hospitalDay 0Exposure Assessment WindowAdministration of famotidine Day [0, 0]D. Design applied in linked EHR-claims dataObservable DataIncomplete ObservabilityNo ObservabilityOutpatient Dx, Px, RxOutpatient Lab resultsInpatient Dx, Px, Rx, LabFollow-upDays [1, censor1]1 Censor on death, discharge, end of study periodIn-hospital death
5. A. Original design visualization frameworkAdministration of PD-(L)1 monotherapy (pembrolizumab, nivolumab, atezolizumab) or PD-(L)1 + doublet chemotherapy combinationDay 0Inclusion Assessment WindowHistorical records of treatment collected by community clinic Days [0, 0]Follow-upDays [1, censor]Day 0Inclusion Assessment WindowRecurrence/progression to aNSCLCDays [-120, 0]Covariate Assessment WindowAge, sex, race, disease stage, histologyDays [0, 0]Covariate Assessment WindowLab testing and result (PD-L1, ALK, eGFR), brain metastasesDays [Jan 1 2011, 30]Covariate Assessment WindowRenal tests and resultDays [-30, 0]Covariate Assessment WindowECOG value (closest to index)Days [-30, 7]Inclusion Assessment Window≥2 visits to community clinic Days [Jan 1 2011, Mar 31 2019]Covariate Assessment WindowSmoking, region, median income (most recent value)Days [Jan 1 2011, 0]Covariate Assessment WindowNon-cancer comorbid conditionsDays [Jan 1 2011, 0]
6. Administration of PD-(L)1 monotherapy (pembrolizumab, nivolumab, atezolizumab) or PD-(L)1 + doublet chemotherapy combinationDay 0Inclusion Assessment WindowHistorical records of treatment collected by community clinic Days [0, 0]Follow-upDays [1, censor]Day 0Inclusion Assessment WindowRecurrence/progression to aNSCLCDays [-120, 0]Covariate Assessment WindowAge, sex, race, disease stage, histologyDays [0, 0]Covariate Assessment WindowLab testing and result (PD-L1, ALK, eGFR), brain metastasesDays [Jan 1 2011, 30]Covariate Assessment WindowRenal tests and resultDays [-30, 0]Covariate Assessment WindowECOG value (closest to index)Days [-30, 7]Inclusion Assessment Window≥2 visits to community clinic Days [Jan 1 2011, Mar 31 2019]Covariate Assessment WindowSmoking, region, median income (most recent value)Days [Jan 1 2011, 0]Covariate Assessment WindowNon-cancer comorbid conditionsDays [Jan 1 2011, 0]B. Design applied in community cancer clinic based EHR database with no external linkage of death dataNon-cancer clinic outpatient Dx, Px, Rx, LabsCancer clinic outpatient Dx, Px, Rx, LabsInpatient Rx, LabInpatient Dx, PxDate of deathObservable DataIncomplete ObservabilityNo Observability
7. Administration of PD-(L)1 monotherapy (pembrolizumab, nivolumab, atezolizumab) or PD-(L)1 + doublet chemotherapy combinationDay 0Inclusion Assessment WindowHistorical records of treatment collected by community clinic Days [0, 0]Follow-upDays [1, censor]Day 0Inclusion Assessment WindowRecurrence/progression to aNSCLCDays [-120, 0]Covariate Assessment WindowAge, sex, race, disease stage, histologyDays [0, 0]Covariate Assessment WindowLab testing and result (PD-L1, ALK, eGFR), brain metastasesDays [Jan 1 2011, 30]Covariate Assessment WindowRenal tests and resultDays [-30, 0]Covariate Assessment WindowECOG value (closest to index)Days [-30, 7]Inclusion Assessment Window≥2 visits to community clinic Days [Jan 1 2011, Mar 31 2019]Covariate Assessment WindowSmoking, region, median income (most recent value)Days [Jan 1 2011, 0]Covariate Assessment WindowNon-cancer comorbid conditionsDays [Jan 1 2011, 0]C. Design applied in community cancer clinic based EHR database with external linkage of death dataNon-cancer clinic outpatient Dx, Px, Rx, LabsCancer clinic outpatient Dx, Px, Rx, LabsInpatient Rx, LabInpatient Dx, PxDate of deathObservable DataIncomplete ObservabilityNo Observability